Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

What happened

Immunome presented additional clinical data for varegacestat, an investigational oral once-daily gamma secretase inhibitor, at the 2026 ESMO Congress. The data appeared in four presentations, including a rapid oral presentation on patient-reported outcomes from the Phase 3 RINGSIDE trial in patients with progressing desmoid tumors.

Confirmed

Global impact / market context

Varegacestat is still investigational, so this data matters for Immunome because it supports the drug's path toward regulatory review in desmoid tumors, a rare disease. Strong symptom and function results could help the company seek approval and eventual revenue, though no launch or approval was announced.

Analyst inference

Desmoid tumor treatments aim beyond tumor shrinkage to relieve symptoms and improve physical function. Reporting patient-reported outcomes at a major oncology congress gives investors a clearer view of varegacestat's competitive profile, but the article discloses no pricing, approval timeline, or financial impact.

Analyst inference

What to watch

1. The rapid oral presentation covered exploratory analyses of patient-reported symptom burden and physical function, complementing pain results previously presented at ASCO 2026. At week 48, the GODDESS TSS-5 symptom score changed by -1.50 with varegacestat versus +0.59 with placebo. Confirmed
2. Watch whether Immunome shares full RINGSIDE results and any regulatory filing plans for varegacestat in desmoid tumors, since those steps would clarify how soon the investigational therapy could reach patients and generate revenue. Proposed
3. Track whether the symptom and function benefits hold across the three posters and larger patient groups, because consistent results would strengthen the case for approval and reduce investor uncertainty about the drug's commercial prospects. Analyst inference

Evidence

• Original source link unavailable